90680-28-7

Basic information

• Product Name: Ethanone, 1-[4-nitro-5-(phenylthio)-2-thienyl]-
• CAS NO: 90680-28-7
• Molecular Formula: C12H9NO3S2
• Molecular Weight: 279.34
• Mol File: 90680-28-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Ethanone, 1-[4-nitro-5-(phenylthio)-2-thienyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-[4-nitro-5-(phenylthio)-2-thienyl]-(90680-28-7)
• EPA Substance Registry System: Ethanone, 1-[4-nitro-5-(phenylthio)-2-thienyl]-(90680-28-7)

Safety Data

• Hazardous Substances Data: 90680-28-7(Hazardous Substances Data)

Usage

General Description

Ethanone, 1-[4-nitro-5-(phenylthio)-2-thienyl]- is a chemical compound that belongs to the class of ketones. It is characterized by a thienyl ring with a nitro group at the 4 position, a phenylthio group at the 5 position, and a carbonyl group at the 1 position. Ethanone, 1-[4-nitro-5-(phenylthio)-2-thienyl]- has potential applications in the field of pharmaceuticals and agrochemicals due to its unique structure and functional groups. It may exhibit various biological activities and can be used as a building block for the synthesis of more complex molecules. However, further research is needed to explore the full potential and properties of this compound.

Upstream product

• 6310-09-4 2-acetyl-5-chlorothiophene 
• 42456-75-7 5-acetyl-2-chloro-3-nitrothiophene 
• 108-98-5 thiophenol 
• 2160-55-6 1-(5-bromo-4-nitro-thiophen-2-yl)-ethanone 

Relevant articles and documents

Selective dual inhibitors of the cancer-related deubiquitylating proteases USP7 and USP47

Inhibitors of the cancer-related cysteine isopeptidase human ubiquitin-specific proteases 7 (USP7) and 47 (USP47) are considered to have potential as cancer therapeutics, owing to their ability to stabilize the tumor suppressor p53 and to decrease DNA polymerase β(Polβ), both of which are potential anticancer effects. A new class of dual small molecule inhibitors of these enzymes has been discovered. Compound 1, a selective inhibitor of USP7 and USP47 with moderate potency, demonstrates inhibition of USP7 in cells and induces elevated p53 and apoptosis in cancer cell lines. Compound 1 has been shown to demonstrate modest activity in human xenograft multiple myeloma and B-cell leukemia in vivo models. This activity may be the result of dual inhibition of USP7 and USP47. To address issues regarding potency and developability, analogues of compound 1 have been synthesized and tested, leading to improvements in potency, solubility, and metabolic reactivity profile. Further optimization is expected to yield preclinical candidates and, ultimately, clinical candidates for the treatment of multiple myeloma, prostate cancer, and other cancers.